CombiMatrix (CBMX) Stock Gains Following ACOG Recommendation

December 5, 2013 7:38 AM EST Send to a Friend
CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that the American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines indicating that chromosomal microarray analysis (CMA) is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen.

The ACOG guidelines also indicate that microarray testing is recommended as the preferred genetic test to help identify the cause of death in stillbirths and intrauterine fetal demise when further cytogenetic analysis is desired because of its increased likelihood of obtaining results and improved detection of causative abnormalities.

CMA is a DNA-based method of prenatal genetic testing. Like the conventional prenatal genetic test known as karyotyping, CMA can identify major chromosomal defects such as Down syndrome. But CMA can also find many other genetic defects that are too small to be detected by karyotyping. Both CMA and karyotyping require testing of fetal tissue obtained with chorionic villus sampling (CVS) or amniocentesis.

"We believe this new guidance from ACOG recommending CMA as the first-line test when an ultrasound reveals one or more major fetal abnormalities is a significant milestone in the evolution of genetic testing for fetal abnormalities, but one that we had expected based on the clinical data from recently published studies," said Mark McDonough, President and CEO. "Due to the support of ACOG and its opinion leaders, we believe clinicians are now more likely to counsel patients on the availability of microarray testing and offer this option to them as a first-line test. We believe ACOG's recognition of microarray testing's increased likelihood of obtaining results and improved detection of causative abnormalities in stillbirths and intrauterine fetal demise also is an important milestone in those areas of care."


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Trader Talk

Add Your Comment